# An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Source: https://onco.cc/trials/nct06634849/  
OnCo record `nct06634849` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PTT-4256 in advanced solid tumours, run by Pathios Therapeutics Pty Ltd, now recruiting.

## Summary

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). is a phase 1/2 interventional study registered as NCT06634849 by Pathios Therapeutics Pty Ltd, with 30 participants planned, started 2024-11-04 and due to reach its primary completion in 2027-04-30. Interventions recorded: PTT-4256.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06634849
- Phase: 1/2
- Setting: A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.
- Sponsor: Pathios Therapeutics Pty Ltd
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06634849: https://clinicaltrials.gov/study/NCT06634849

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06634849.json